Status:
COMPLETED
Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Graft Versus Host Disease
Leukemia
Eligibility:
All Genders
Up to 65 years
Phase:
PHASE3
Brief Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the growth of cancer and abnormal cells and helps st...
Detailed Description
OBJECTIVES: * Compare the effectiveness, in terms of incidence of graft failure and incidence of greater than grade 1 acute graft-vs-host disease, of ex vivo manipulation of bone marrow cells compris...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of 1 of the following hematologic malignancies or genetic disorders:
- Acute myeloid leukemia (AML), meeting 1 of the following criteria
- Primary resistant disease
- Disease in complete remission (CR)
- Disease in first early relapse
- Secondary AML arising out of myelodysplastic syndrome
- Acute lymphocytic leukemia (ALL), meeting 1 of the following criteria:
- Primary resistant disease
- Disease in CR
- Disease in first early relapse
- Chronic myelogenous leukemia
- Myelodysplastic syndrome (MDS)
- Chronic myelomonocytic leukemia
- Philadelphia chromosome-negative myeloproliferative disorder
- Multiple myeloma
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma
- Genetic disorders or inborn errors of metabolism
- Planning allogeneic bone marrow transplantation at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Medical Center
- Must have an HLA-identical sibling donor by serologic or molecular typing of HLA class I antigens and molecular typing of HLA class II antigens
- PATIENT CHARACTERISTICS:
- Performance status
- Not specified
- Life expectancy
- Not specified
- Hematopoietic
- Not specified
- Hepatic
- Not specified
- Renal
- Not specified
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- No prior red blood cell or platelet transfusion from the same donor
- Other
- Concurrent participation in another clinical trial allowed
Exclusion
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00265837
Start Date
December 1 2002
End Date
August 1 2007
Last Update
April 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410